Yu Chen

Shanghai Jiao Tong University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Shunlin Hu

Yangzhou University

Junxiao Liu

Northeastern University

Chaohu Pan

Shenzhen Third People’s Hospital

Wancheng Liu

Qilu Hospital of Shandong University

Heng Yang

South China Agricultural University

Yu Rao

Soochow University

Qiaomei Cai

Chinese Academy of Medical Sciences & Peking Union Medical College

Lili Li

Chinese Academy of Medical Sciences & Peking Union Medical College

Genhong Cheng

University of California, Los Angeles

Liguo Wang

Mayo Clinic

Cooperative Institutions

Zhejiang University

Shanghai Jiao Tong University

Yangzhou University

Chinese Academy of Medical Sciences & Peking Union Medical College

First Affiliated Hospital Zhejiang University

Peking University

Capital Medical University

Chinese Academy of Sciences

Ministry of Agriculture and Rural Affairs

Nanjing Medical University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses

Yu Chen Qiaomei Cai Chaohu Pan Wancheng Liu Lili Li

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses

Table (database)

10.1158/2326-6066.22544232.v1

Cite

Citations (0)

Analysis of clinical features of COVID-19 in cancer patients

Figshare (2020)

Weiting Cheng Yuhe Ke Guang-Yan Yang Hong Sun Yu Chen

Analysis of clinical features of COVID-19 in cancer patients

2019-20 coronavirus outbreak

10.6084/m9.figshare.12888569

Cite

Citations (0)

Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B

Antiviral Research (2011)

Yu Chen Xuefen Li Bo Ye Xianzhi Yang Wei Wu

Telbivudine

HBcAg

HBeAg

Hepatitis B

10.1016/j.antiviral.2011.04.008

Cite

Citations (54)

JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B

Life Sciences (2020)

Yuejiao Dong Xuefen Li Yanying Yu Feifei Lv Yu Chen

STAT4

Tyrosine kinase 2

10.1016/j.lfs.2020.117663

Cite

Citations (32)

Correlation between peripheral blood CD4⁺CD25⁺ Treg cells and disease progression and prognosis in HBV carriers: A Meta-analysis

Shijie huaren xiaohua zazhi (2013)

Zong-Qin Pan Hong Lv Shiyun Hu Yu Chen Qin-Jian Zhuang

10.11569/wcjd.v21.i29.3124

Cite

Citations (0)

Changes of Costimulatory Molecule CD28 on Circulating CD8⁺T Cells Correlate with Disease Pathogenesis of Chronic Hepatitis B

BioMed Research International (2014)

Xuefen Li Haishen Kong Tian Li Qiaoyun Zhu Yiyin Wang

Costimulatory signals are critical for antiviral immunity. The aim of this study was to evaluate the change of costimulatory molecule CD28 on circulating CD8 + T cells in chronic hepatitis B patients (CHB). Seventy CHB patients and fifty-six healthy controls were included, and forty-eight CHB patients were recruited for 52 weeks of longitudinal investigation. The proportions of circulating CD8 + CD28 + and CD8 + CD28 − subpopulations were determined by flow cytometry, and the CD8 + CD28 + /CD8 + CD28 − T cells ratio was calculated. Compared with the subpopulation in healthy controls, high proportions of CD8 + CD28 − subpopulation were observed in CHB patients. Similarly, the CD8 + CD28 + /CD8 + CD28 − T cells ratio was significantly decreased in CHB patients compared with healthy controls and correlated significantly with hepatitis B virus (HBV) loads. High proportions of CD8 + CD28 − subpopulation and low CD8 + CD28 + /CD8 + CD28 − T cells ratio were observed in hepatitis B e antigen- (HBeAg-) positive individuals as compared with that in HBeAg-negative subjects. A significant decrease in CD8 + CD28 − subpopulation, increase in CD8 + CD28 + subpopulation, and CD8 + CD28 + /CD8 + CD28 − T cells ratio were seen in those patients who received efficient antiviral therapy. Thus, aberrant CD28 expression on circulating CD8 + T cells and the CD8 + CD28 + /CD8 + CD28 − T cells ratio reflect the dysregulation of T cell activation and are related to the pathogenesis of chronic HBV infection.

Pathogenesis

10.1155/2014/423181

Cite

Citations (14)

Development and Evaluation of a Newcastle Disease Virus-like Particle Vaccine Expressing SARS-CoV-2 Spike Protein with Protease-Resistant and Stability-Enhanced Modifications

Viruses (2024)

Yu Chen Tian Fan Shunlin Hu Xiufan Liu

The ongoing global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the continuous development of innovative vaccine strategies, especially in light of emerging viral variants that could undermine the effectiveness of existing vaccines. In this study, we developed a recombinant virus-like particle (VLP) vaccine based on the Newcastle Disease Virus (NDV) platform, displaying a stabilized prefusion form of the SARS-CoV-2 spike (S) protein. This engineered S protein includes two proline substitutions (K986P, V987P) and a mutation at the cleavage site (RRAR to QQAQ), aimed at enhancing both its stability and immunogenicity. Using a prime-boost regimen, we administered NDV-VLP-S-3Q2P intramuscularly at different doses (2, 10, and 20 µg) to BALB/c mice. Robust humoral responses were observed, with high titers of S-protein-specific IgG and neutralizing antibodies against SARS-CoV-2 pseudovirus, reaching titers of 1:2200–1:2560 post-boost. The vaccine also induced balanced Th1/Th2 immune responses, evidenced by significant upregulation of cytokines (IFN-γ, IL-2, and IL-4) and S-protein-specific IgG1 and IgG2a. Furthermore, strong activation of CD4+ and CD8+ T cells in the spleen and lungs confirmed the vaccine’s ability to promote cellular immunity. These findings demonstrate that NDV-S3Q2P-VLP is a potent immunogen capable of eliciting robust humoral and cellular immune responses, highlighting its potential as a promising candidate for further clinical development in combating COVID-19.

Immunogen

Newcastle Disease

Humoral immunity

Virus-like particle

10.3390/v16121932

Cite

Citations (0)

So far away from me: Firm location and the managerial ownership effect on firm value

Journal of Corporate Finance (2020)

Bradley W. Benson Yu Chen Hui L. James Jung Chul Park

Endogeneity

Expropriation

Value (mathematics)

Simultaneity

Sample (material)

Investment

Observability

10.1016/j.jcorpfin.2020.101658

Cite

Citations (21)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses

Yu Chen Qiaomei Cai Chaohu Pan Wancheng Liu Lili Li

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses

Table (database)

10.1158/2326-6066.22544241.v1

Cite

Citations (0)

Heterogeneous nuclear ribonucleoprotein A2B1, a novel drug target for hepatitis B virus infection

Research Square (Research Square) (2021)

Min Xu Yu Chen Hao-Yan Yuan Yuehai Shen Jia‐Yao Xiang

Abstract HBV infection is a major global health burden that needs novel immunotherapeutic approaches. Herein, we show that heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) is a novel drug target for HBV infection. We reveal the new target with highly selective probes of PAC5, a natural sesquiterpene derivative. PAC5 show potent anti-HBV activity in vivo and in vitro. Further studies on its mode of action indicate that PAC5 binds to the residue Asp49 and a deep groove in the RNA recognition motif1 (RRM1) region of hnRNPA2B1. PAC5-bound hnRNPA2B1 is activated, dimerized, and translocated to the cytoplasm where it activates the TBK1-IRF3 pathway, leading to the production of type I interferons (IFNs). Furthermore, PAC5 also suppresses other viral replications, such as SARS-CoV-2 and vesicular stomatitis virus (VSV). Our results indicate that PAC5 is the first small molecule agonist of hnRNPA2B1, a drug target potentially valid for broad-spectrum viral infections, providing a novel strategy for viral immunotherapy.

Feline calicivirus

Heterogeneous nuclear ribonucleoprotein

Antiviral drug

10.21203/rs.3.rs-418051/v1

Cite

Citations (0)